GSK 202405Alternative Names: 202405
Latest Information Update: 05 Dec 2007
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action Muscarinic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 30 Nov 2004 Phase-II clinical trials in Chronic obstructive pulmonary disease (unspecified route)